BLUEPRINT MEDICINES CORP
BLUEPRINT MEDICINES CORP
Share · US09627Y1091 · BPMC · A14SDD (XNAS)
Overview Financial Indicators
127,97 USD
-0,19 % -0,24 USD
NASDAQ (XNAS) · Current prices and charts at MoneyPeak
13.06.2025 14:51

Current Prices from BLUEPRINT MEDICINES CORP

ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
BPMC
USD
13.06.2025 14:51
127,97 USD
128,21 USD
-0,19 %
XLON: London
London
0HOJ.L
USD
13.06.2025 14:30
128,07 USD
128,21 USD
-0,11 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
-0,19 % 0,16 % 27,57 % 41,40 % 38,23 % 18,66 % 83,10 %

Company Profile for BLUEPRINT MEDICINES CORP Share

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Invested Funds

The following funds have invested in: BLUEPRINT MEDICINES CORP invested:

Fund
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. in million
190,44
Percentage (%)
0,45 %

Company Data

Name BLUEPRINT MEDICINES CORP
Company Blueprint Medicines Corporation
Symbol BPMC
Website https://www.blueprintmedicines.com
Primary Exchange XNAS NASDAQ
WKN A14SDD
ISIN US09627Y1091
Asset Class Share
Sector Healthcare
Industry Medical - Pharmaceuticals
CEO Ms. Kathryn Haviland M.B.A.
Market Capitalization 5 Mrd.
Country United States of America
Currency USD
Employees 0,6 T
Address 45 Sidney Street, 02139 Cambridge
IPO Date 2018-01-29

Ticker Symbols

Name Symbol
Frankfurt 2L9.F
London 0HOJ.L
NASDAQ BPMC

More Shares

Investors who BLUEPRINT MEDICINES CORP hold also have the following shares in their portfolio:
AMGEN INC
AMGEN INC Share
APPLE INC
APPLE INC Share
AUTODESK INC
AUTODESK INC Share
BASLER KT.BK 20/32
BASLER KT.BK 20/32 Bond
BQX
BQX Crypto
CISCO SYSTEMS INC
CISCO SYSTEMS INC Share
COSTCO WHOLESALE CORP
COSTCO WHOLESALE CORP Share
HESS CORP
HESS CORP Share
LAM RESEARCH CORP
LAM RESEARCH CORP Share
MICROCHIP TECHNOLOGIESLOGY INC
MICROCHIP TECHNOLOGIESLOGY INC Share
MICROSOFT CORP
MICROSOFT CORP Share
NETFLIX INC
NETFLIX INC Share
O'REILLY AUTOMOTIVE INC
O'REILLY AUTOMOTIVE INC Share
VANECK MULT.A GROW.UC.ETF
VANECK MULT.A GROW.UC.ETF Share
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025